Page URL: https://www.bionews.org.uk/page_149720

First epigenetic study in 3D human cancer cells

18 May 2020
Appeared in BioNews 1047

Researchers have, for the first time, characterised the epigenetic profile of tumour organoids and made their results available in public databases.

Cancer research is often conducted on two dimensional (2D) models of tumours, such as cancer cells grown in a tissue culture dish. Recently, three dimensional (3D) models have become more widely used. These 3D models – or tumour organoids – can be created from human cancer cells and are grown with a more realistic 3D structure.

Dr Manel Esteller, director of the Joseph Carreras Leukaemia Research Institute, Spain, explains: 'Our study shows that these tumour models can be very useful for the biomedical research community and the pharmaceutical companies developing anti-cancer drugs.' 

The research team, led by Dr Manel Esteller, looked at 25 human cancer organoids from the American Type Culture Collection (ATCC) and analysed their epigenetic profiles. Epigenetic profiles are modifications of DNA that can alter which parts of the genetic code are used within a cell. One such epigenetic modification is DNA methylation. The research, published in the journal Epigenetics, found that the DNA methylation patterns in the organoids corresponded more closely to the tumour they originated from than to established 2D cell lines.

This research promises to fill the gap in knowledge about epigenetic profiles of organoids and to provide an alternative to 2D cultures which might not be the most reliable tool for predicting which therapies work well in the clinic. Many compounds that look promising when tested in 2D cell lines show no benefit when used in patients. One possible cause is that 2D cancer cell lines have often been established several decades ago and are grown in a less natural 2D format.

Perhaps most importantly, the groups’ results are available to other researchers via public databases. Dr Esteller explains the implications: 'We have deposited all the obtained results in easily accessible public databases, and, in this manner, everyone can perform further data mining to produce new cancer discoveries using different biometric approaches or focusing on particular genes. And most importantly, the characterised cancer organoids can be readily obtainable from a reliable provider (the ATCC), so researchers around the world can use the epigenetic information of these sharable samples to develop their investigations.'

SOURCES & REFERENCES
Cancer research breakthrough as DNA behavior is uncovered in 3D models
Innovations Report |  11 May 2020
First Epigenetic Study in 3D Human Cancer Cells
Josep Carrera Leukeamia Institute |  13 May 2020
The DNA methylation landscape of human cancer organoids available at the American type culture collection
Epigenetics |  12 May 2020
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
5 October 2020 - by Dr Barbara Kramarz 
Although we have known of the interactions of nature and nurture for decades, the term 'epigenetics' has only recently been taken up by scientists and the wider public to refer to these phenomena...
29 June 2020 - by Dr Joanne Delange 
A new drug targeting a cancer's ability to repair its DNA has shown favourable results in its first clinical trial...
10 December 2018 - by Charlott Repschlager 
Australian researchers have developed a cancer test, which could potentially detect cancerous DNA in blood and tissue samples in under 10 minutes...
22 October 2018 - by Isobel Steer 
Researchers have identified a DNA methylation signature that can identify aggressive prostate cancer, with up to 92 percent accuracy...
4 August 2014 - by Daryl Ramai 
Scientists at the Children's Nutrition Research Center, USA have shown that epigenetic changes alone could cause cancer....
HAVE YOUR SAY
Log in to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.